Single-cell multiomics — the simultaneous measurement of multiple molecular layers (gene expression, chromatin accessibility, protein surface markers, spatial location) within individual cells rather than bulk tissue populations — creating a revolution in biological understanding by revealing the cellular heterogeneity, developmental trajectories, and cell state transitions masked by bulk averaging, and representing the most rapidly growing technology segment within the Multiomics Market as single-cell platforms achieve dramatically reduced cost per cell and expanded simultaneous measurement capability.

10x Genomics' market-defining position — the dominant commercial single-cell multiomics platform provider with Chromium Single Cell RNA + ATAC + Protein (CITE-seq capability) enabling simultaneous transcriptome, chromatin accessibility, and surface proteome measurement from the same single cell, providing the regulatory state (ATAC), expression state (RNA), and protein state (CITE) required for comprehensive cell characterization. 10x Genomics' Visium spatial transcriptomics and Xenium in situ platform extensions adding spatial coordinates to single-cell molecular measurements — enabling researchers to understand not just what a cell is doing molecularly but where it is doing it within tissue architecture, which is critical for understanding tumor microenvironments, developmental tissue organization, and disease-associated spatial cellular reorganization.

CITE-seq and multimodal single-cell protein measurement — the combined measurement of transcriptomic (mRNA) and proteomic (surface protein) information from single cells using DNA-barcoded antibodies (totalSeq reagents, BioLegend) measured simultaneously with RNA in the 10x Genomics droplet platform. CITE-seq enabling protein-level confirmation of cell type identity alongside transcriptome-based classification — resolving ambiguities in cell typing where RNA expression and protein abundance are discordant due to post-transcriptional regulation, and enabling immunological cell type classification using the established protein-based nomenclature (CD markers) alongside transcriptomic data.

Single-cell multiomics in tumor biology revealing immunotherapy response mechanisms — the application of scRNA-seq, scATAC-seq, and spatial transcriptomics to tumor biopsies before and during immunotherapy treatment revealing the cellular and molecular basis of response and resistance at unprecedented resolution. Landmark studies identifying T cell exhaustion states, regulatory T cell infiltration patterns, tumor cell plasticity, and myeloid cell polarization states in tumors as predictors of immunotherapy response — with clinical biomarker programs at Genentech, BMS, and Merck incorporating single-cell multiomics to develop companion diagnostics for PD-1/PD-L1 checkpoint inhibitor selection.

Do you think single-cell multiomics will eventually be cost-effective enough for routine clinical diagnostic use, enabling single-cell resolved tumor characterization for every cancer patient, or will the data volume, analysis complexity, and clinical interpretation challenges maintain single-cell approaches in research and specialized clinical applications for the foreseeable future?

FAQ

What computational methods are used for single-cell multiomics data analysis? Single-cell multiomics computational pipeline: preprocessing: Cell Ranger (10x Genomics) — read alignment, cell barcode demultiplexing, UMI count matrix generation; quality control: Scanpy (Python) or Seurat (R) — filtering low-quality cells (low UMI, high mitochondrial gene fraction); doublet detection (Scrublet, DoubletFinder); normalization: scran (pooling-based normalization); SCTransform (variance-stabilizing normalization in Seurat); dimensionality reduction: PCA → UMAP/t-SNE for visualization; LSI for ATAC-seq; clustering: Leiden or Louvain algorithms for cell clustering; resolution parameter tuning; cell type annotation: marker gene scoring (SingleR, scType automatic annotation); manual expert annotation from known markers; trajectory analysis: RNA velocity (scVelo — predicting cellular developmental direction from unspliced:spliced RNA ratio); Monocle3, PAGA (trajectory inference); multimodal integration: WNN (weighted nearest neighbor, Seurat v4) integrating RNA + protein; MOFA+ for multi-sample multiomics; ArchR for scATAC analysis; Signac (Seurat extension for epigenomics); spatial analysis: Squidpy (spatial statistics), BayesSpace (spatial clustering); cell-cell communication: CellChat, CellPhoneDB (ligand-receptor interaction prediction from single-cell data); differential expression: MAST, DESeq2, EdgeR adapted for single-cell; batch correction: Harmony, scVI, BBKNN; computing infrastructure: typically cloud-based (AWS, Google Cloud) for large datasets; Snakemake/Nextflow workflow management; storage: ~50GB per 10,000-cell RNA-seq experiment; TB-scale for large atlas projects.

What are the key applications of spatial transcriptomics in understanding disease biology? Spatial transcriptomics applications in disease research: tumor microenvironment: mapping spatial organization of tumor cells, T cells, macrophages, fibroblasts — understanding how cell-cell communication and spatial proximity influence immunotherapy response; identifying tumor-immune interface (margin) molecular signatures predicting response; neuroscience: brain circuit mapping — correlating cell type location with gene expression and connectivity; Alzheimer's disease spatial plaque-associated transcriptome changes; neuronal layer-specific gene expression in brain cortex; cardiac: cardiac fibrosis spatial mapping; cardiomyocyte regional gene expression changes in heart failure; infarct border zone characterization; development: embryonic tissue patterning — spatial gene expression waves directing organogenesis; gastrulation and body axis formation; liver zonation: hepatocyte zone-specific metabolism gene expression gradients from pericentral to periportal regions; disease implications for zone-specific toxicity; gut: crypt-villus axis spatial gene expression; IBD lesion spatial transcriptomics — identifying active inflammation versus healing zones; microbiome interaction with epithelial spatial transcriptome; kidney: nephron segment-specific gene expression; glomerular disease spatial transcriptomics; commercial platforms: 10x Visium (55µm spots, ~4,000 spots/section); 10x Xenium (single-molecule resolution, 313-gene panel); Nanostring CosMx (1,000-gene single-cell resolution); Vizgen MERSCOPE (MERFISH — thousands of genes, single molecule); Resolve Biosciences Molecular Cartography; clinical translation: Akoya Biosciences PhenoCode panels for clinical spatial proteomics; NCI Human Tumor Atlas Network using spatial multiomics.